0
     

Report Added
Report already added
Active Pharmaceutical Ingredients (API) Global Market - Forecast To 2027

Active Pharmaceutical Ingredients (API) Global Market - Forecast To 2027

Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to IQ4I analysis, the global Active Pharmaceutical Ingredient market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $364,169.4 million by 2027. Adoption of biologics in disease management and increasing regulatory approvals in the past year, increasing scope of HPAPI market, patent expiration of major drugs, increasing trend of outsourcing, and increase in geriatric population are some of the factors driving the market growth. The global API market is mainly segmented by synthesis, by business type, by application, and by geography.
The global API market based on synthesis is further divided into synthetic API, Biotech API, and HPAPI. By synthesis, the synthetic API held the major share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The major factors driving the synthetic chemical API market are patent expiration of synthetic (small molecule drugs), an increasing number of small molecules in clinical trials, increasing outsourcing by the pharmaceutical companies, CMOs investments to expand manufacturing facilities, rise in the incidence of chronic and age-related diseases, rapid growth in the oncology market, technological advancement like cryogenic and continuous flow manufacturing. Biotech API accounted for the share of xx% in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. Increased investment in R&D by pharmaceutical companies for developing biologic drugs, adoption of biological therapies in disease management, increasing outsourcing, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, increasing number of branded drugs going off-patent creating a scope for biosimilars, requirement of novel biologics therapeutics for rare diseases, increasing demand for antibody conjugates, bi or multispecific monoclonal antibodies, and vaccines to contain novel coronavirus infections are few factors driving the biotech API market.
Biotech API is further segmented into monoclonal antibodies, recombinant proteins, vaccines, and others (stem cell therapy and gene therapy). Monoclonal antibodies accounted for the largest share in 2020 and are expected to grow at a high single digit CAGR from 2020 to 2027. The development of next-generation antibodies such as antibody-drug conjugates and rising venture capital investments and applications of monoclonal antibodies are the factors booming monoclonal antibodies market growth. The vaccine segment is forecasted to grow at a low teen CAGR from 2020 to 2027 owing to the worldwide demand for novel vaccines to treat the coronavirus diseases which emerged as a global pandemic.
Based on the customer base, the global biotech API is further segmented into biologics and biosimilars. Biologics accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The Biologics market is driven globally due to the adoption of biological therapies in disease management, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, and increasing the elderly population. Biosimilars accounted for the share of xx% in 2020 and is expected to grow at an exponential CAGR from 2020 to 2027 owing to patent expiry of biological drugs, low cost compared to biologics, increase in chronic diseases, growing geriatric population, and demand for quality healthcare.
Based on the customer base, the global synthetic API is further divided into branded API and generic API. The Branded API accounted for the largest share in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. The Generic API is expected to grow at a high single digit CAGR from 2020 to 2027, due to the patent expiry of blockbuster drugs, rising healthcare expenses, and shift towards generic medicines led by government initiatives.
By business type, the global API market is divided into captive API and merchant API. The Captive market held the major share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The captive API is further divided into branded captive API and generic captive API. The branded captive API accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027 owing to patent protection of blockbuster drugs. The Merchant API market is further divided into branded merchant API and generic merchant API. The Generic merchant API accounted for the largest share in 2020 and is expected to grow at a low teen CAGR from 2020 to 2027. Increasing outsourcing, advanced manufacturing facilities, lack of in-house manufacturing capability, high capital investment, and cost of API manufacturing are some of the factors driving the Merchant API market.
By therapeutic applications, the global API market is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculoskeletal disorders, and others such as others such as ophthalmology, autoimmune diseases, ENT, dental, dermatology, and pain management. In the application segment, infectious disease accounted for the largest share in 2020 because of the global-wide rapid spread of COVID-19 and increased incidence of other infectious diseases such as tuberculosis, HIV, pneumonia, influenza, hepatitis, and others. The oncology division is expected to grow at a double digit CAGR from 2020 to 2027 driven mainly by the rising incidence of cancer cases, lifestyle changes, increasing geriatric population, high demand for anti-cancer drugs. Currently, there is a trend towards precision medicine which further boosts the global oncology API market growth.
The global API market by therapeutic application is segmented into synthetic API application, biotech API application, and HPAPI application market. In synthetic API application, infectious disease accounted for the largest share in 2020 and oncology is expected to grow at a high single digit CAGR from 2020 to 2027. Under biotech API and HPAPI, the oncology segmented contributed for the largest share of xx% and xx% in 2020 respectively, and is forecasted to grow at a high single digit CAGR of xx% and xx% from 2020 to 2027.
The active pharmaceutical Ingredients market by region is segmented as North America, Europe, Asia-Pacific, and the Rest of the world (ROW). By geography, North America held the largest share in 2020 due to patent expiration of the major drugs, rising demand for biotech APIs, market entry of biosimilars, increasing scope of highly potent drugs, and increase in the prevalence of chronic diseases such as cancer, cardiac disease, diseases associated with central nervous system, and musculoskeletal disorder coupled with high healthcare expenditure. Asia-Pacific is the fastest-growing region with a high single digit CAGR from 2020 to 2027 owing to low labor cost, abundance availability of raw materials, infrastructure facility, rise in generic drug demand, increased production capabilities, the presence of a large number of domestic and international players, and concentration of CMO companies.
Some of the key players of Active pharmaceutical Ingredient (API) market are Lonza Group (Switzerland), Boehringer Ingelheim GmbH (Germany), Teva Pharmaceutical Industries Ltd (Israel), Sanofi S.A. (France), Thermo Fisher Sceintific Inc. (Patheon N.V, U.S), Divis Laboratories (India), Olon S.p.A (Italy), Pfizer Inc. (U.S.), Permira funds (Cambrex Corporation U.K.), Carlyle Group (AMRI, U.S.), and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Rest of North America
• Europe
o Italy
o Germany
o France
o Rest of Europe
• Asia-Pacific
o China
o Japan
o India
o Rest of APAC
• Rest of the World (RoW)
o Brazil
o Rest of Latin America
o Middle East and Others

1 EXECUTIVE SUMMARY 28
2 INTRODUCTION 36
2.1 KEY TAKEAWAYS 36
2.2 SCOPE OF THE REPORT 37
2.3 REPORT DESCRIPTION 37
2.4 MARKETS COVERED 41
2.5 STAKEHOLDERS 43
2.6 RESEARCH METHODOLOGY 43
2.6.1 MARKET SIZE ESTIMATION 45
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 47
2.6.3 SECONDARY SOURCES 48
2.6.4 PRIMARY SOURCES 49
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 50
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 51
2.6.7 ASSUMPTIONS 52
3 MARKET ANALYSIS 54
3.1 INTRODUCTION 54
3.2 MARKET SEGMENTATION 55
3.3 FACTORS INFLUENCING MARKET 57
3.3.1 DRIVERS AND OPPORTUNITIES 58
3.3.1.1 Increasing incidence and prevalence of chronic diseases 58
3.3.1.2 Adoption of biologics in disease management and increasing regulatory approvals in the past year 60
3.3.1.3 Increasing scope of HPAPI market 62
3.3.1.4 Patent expiration of major drugs 63
3.3.1.5 Increasing trend of outsourcing 64
3.3.1.6 Increase in the geriatric population 65
3.3.2 RESTRAINTS AND THREATS 66
3.3.2.1 Contamination of API 66
3.3.2.2 High cost for manufacturing APIs 67
3.3.2.3 A requirement of highly skilled technicians 68
3.3.2.4 Fierce competition between API players 69
3.3.2.5 Stringent regulatory policies and environmental concerns 70
3.4 REGULATORY AFFAIRS 72
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 72
3.4.1.1 ISO 9001: 2015 quality management system 73
3.4.1.2 ISO 13408 aseptic processing 73
3.4.1.3 ISO 14644-1 clean room standards 73
3.4.2 U.S. 73
3.4.3 CANADA 76
3.4.4 MEXICO 77
3.4.5 EUROPE 77
3.4.6 CHINA 79
3.4.7 INDIA 80
3.4.8 JAPAN 82
3.4.9 AUSTRALIA 83
3.4.10 SOUTH KOREA 83
3.4.11 LATIN AMERICA 84
3.4.12 MIDDLE EAST 84
3.5 TECHNOLOGICAL ADVANCEMENTS 85
3.5.1 INTRODUCTION 85
3.5.2 AUTOMATION AND CONTROL 85
3.5.3 CONTINUOUS MANUFACTURING 86
3.5.4 CRYOGENIC TECHNOLOGY 88
3.5.5 SINGLE - USE SYSTEM (SUS) 89
3.5.6 MAMMALIAN CELL BASED PRODUCTION 90
3.5.7 CELL FREE BASED APPROACH FOR THE PRODUCTION OF PROTEINS 90
3.5.8 ADVANCEMENTS IN HPAPI MANUFACTURING 91
3.6 PORTER’S FIVE FORCE ANALYSIS 92
3.6.1 THREAT OF NEW ENTRANTS 93
3.6.2 THREAT OF SUBSTITUTES 93
3.6.3 BARGAINING POWER OF SUPPLIERS 94
3.6.4 BARGAINING POWER OF BUYERS 95
3.6.5 COMPETITIVE RIVALRY 95
3.7 SUPPLY CHAIN ANALYSIS 97
3.8 MARKET SHARE ANALYSIS 104
3.9 FDA APPROVED API MANUFACTURING UNITS 107
3.10 PHARMACEUTICAL API PRODUCTION VOLUME 109
3.11 PATENT EXPIRY AND ANDA APPROVALS 117
3.12 DRUG MASTER FILING (DMF) 132
3.13 NOTICE OF INSPECTIONAL OBSERVATIONS (FORM 483) 137
3.14 REPURPOSED DRUGS FOR COVID-19 TREATMENT 139
3.15 ACQUISITION, MERGER, AND EXPANSIONS 143
3.16 COLLABORATION AND AGREEMENT BETWEEN API MANUFACTURERS 156
3.17 SELECTED TOP SELLING API 160
3.18 API MANUFACTURERS REVENUE AND CAPABILITIES TABLE 184
4 API GLOBAL MARKET, BY SYNTHESIS 201
4.1 INTRODUCTION 201
4.2 SYNTHETIC API 204
4.2.1 SYNTHETIC API BY CUSTOMER BASE 207
4.2.1.1 Branded synthetic API 209
4.2.1.2 Generic synthetic API 211
4.3 BIOTECH API 213
4.3.1 INTRODUCTION 213
4.3.1.1 Monoclonal antibodies 218
4.3.1.2 Recombinant proteins 223
4.3.1.3 Vaccines 226
4.3.1.4 Other biotech API (cell and gene therapy) 231
4.3.2 BIOTECH API BY CUSTOMER BASE 236
4.3.2.1 Biologic API 238
4.3.2.2 Biosimilar API 241
4.4 HPAPI 244
4.4.1 HPAPI BY CUSTOMER BASE 247
4.4.1.1 Branded HPAPI 249
4.4.1.2 Generic HPAPI 251
5 API GLOBAL MARKET, BY BUSINESS TYPE 254
5.1 INTRODUCTION 254
5.2 CAPTIVE API BY TYPE 257
5.2.1 BRANDED CAPTIVE API 261
5.2.2 GENERIC CAPTIVE API 263
5.3 MERCHANT API BY TYPE 265
5.3.1 BRANDED MERCHANT API 268
5.3.2 GENERIC MERCHANT API 270
6 API GLOBAL MARKET, BY APPLICATION 272
6.1 INTRODUCTION 272
6.2 INFECTIOUS DISEASES 281
6.3 ONCOLOGY 293
6.4 CARDIOVASCULAR DISEASES 303
6.5 CENTRAL NERVOUS SYSTEM 310
6.6 PULMONARY DISORDERS 317
6.7 GASTROINTESTINAL DISORDERS 323
6.8 ENDOCRINE DISORDERS 329
6.9 METABOLIC DISORDERS 335
6.10 GENITOURINARY DISORDERS 343
6.11 MUSCULOSKELETAL DISORDERS 348
6.12 OTHER APPLICATIONS (ANAESTHASIA, AUTOIMMUNE DISEASES, OPTHALMOLOGY, DENTAL, PAIN MANAGEMENT, GYNAECOLOGY, DERMATOLOGY AND ENT) 354
7 REGIONAL ANALYSIS 361
7.1 INTRODUCTION 361
7.2 NORTH AMERICA 366
7.2.1 U.S. 391
7.2.2 REST OF NORTH AMERICA 401
7.3 EUROPE 410
7.3.1 ITALY 436
7.3.2 GERMANY 444
7.3.3 FRANCE 452
7.3.4 REST OF EUROPE 460
7.4 APAC 469
7.4.1 CHINA 494
7.4.2 JAPAN 504
7.4.3 INDIA 512
7.4.4 REST OF APAC 524
7.5 ROW 533
7.5.1 BRAZIL 556
7.5.2 REST OF LATAM 564
7.5.3 MIDDLE EAST & OTHERS 571
8 COMPETITIVE LANDSCAPE 578
8.1 INTRODUCTION 578
8.2 PRODUCT APPROVALS 579
8.3 AGREEMENTS 590
8.4 EXPANSIONS 598
8.5 COLLABORATIONS 603
8.6 PRODUCT LAUNCH 607
8.7 PARTNERSHIP 610
8.8 ACQUISITIONS 612
8.9 OTHERS 615
9 MAJOR COMPANIES 619
9.1 CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC) 619
9.1.1 OVERVIEW 619
9.1.2 FINANCIALS 620
9.1.3 PRODUCT PORTFOLIO 620
9.1.4 KEY DEVELOPMENTS 620
9.1.5 BUSINESS STRATEGY 622
9.1.6 SWOT ANALYSIS 623
9.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 624
9.2.1 OVERVIEW 624
9.2.2 FINANCIALS 625
9.2.3 PRODUCT PORTFOLIO 628
9.2.4 KEY DEVELOPMENTS 628
9.2.5 BUSINESS STRATEGY 632
9.2.6 SWOT ANALYSIS 633
9.3 DIVIS LABORATORIES 634
9.3.1 OVERVIEW 634
9.3.2 FINANCIALS 635
9.3.3 PRODUCT PORTFOLIO 637
9.3.4 KEY DEVELOPMENTS 637
9.3.5 BUSINESS STRATEGY 638
9.3.6 SWOT ANALYSIS 639
9.4 LONZA GROUP LTD. 640
9.4.1 OVERVIEW 640
9.4.2 FINANCIALS 641
9.4.3 PRODUCT PORTFOLIO 644
9.4.4 KEY DEVELOPMENTS 644
9.4.5 BUSINESS STRATEGY 649
9.4.6 SWOT ANALYSIS 650
9.5 OLON S.P.A. 651
9.5.1 OVERVIEW 651
9.5.2 FINANCIALS 652
9.5.3 PRODUCT PORTFOLIO 652
9.5.4 KEY DEVELOPMENTS 652
9.5.5 BUSINESS STRATEGY 653
9.5.6 SWOT ANALYSIS 654
9.6 PERMIRA FUNDS (CAMBREX CORPORATION U.K.) 655
9.6.1 OVERVIEW 655
9.6.2 FINANCIALS 656
9.6.3 PRODUCT PORTFOLIO 656
9.6.4 KEY DEVELOPMENTS 657
9.6.5 BUSINESS STRATEGY 659
9.6.6 SWOT ANALYSIS 660
9.7 PFIZER INC. 661
9.7.1 OVERVIEW 661
9.7.2 FINANCIALS 662
9.7.3 PRODUCT PORTFOLIO 665
9.7.4 KEY DEVELOPMENTS 665
9.7.5 BUSINESS STRATEGY 672
9.7.6 SWOT ANALYSIS 673
9.8 SANOFI 674
9.8.1 OVERVIEW 674
9.8.2 FINANCIALS 675
9.8.3 PRODUCT PORTFOLIO 678
9.8.4 KEY DEVELOPMENTS 678
9.8.5 BUSINESS STRATEGY 684
9.8.6 SWOT ANALYSIS 685
9.9 TEVA PHARMACEUTICAL INDUSTRIES LIMITED. 686
9.9.1 OVERVIEW 686
9.9.2 FINANCIALS 687
9.9.3 PRODUCT PORTFOLIO 690
9.9.4 KEY DEVELOPMENTS 691
9.9.5 BUSINESS STRATEGY 693
9.9.6 SWOT ANALYSIS 694
9.10 THERMO FISHER SCIENTIFIC INC 695
9.10.1 OVERVIEW 695
9.10.2 FINANCIALS 696
9.10.3 PRODUCT PORTFOLIO 699
9.10.4 KEY DEVELOPMENTS 699
9.10.5 BUSINESS STRATEGY 701
9.10.6 SWOT ANALYSIS 702

LIST OF TABLES
TABLE 1 API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 34
TABLE 2 GLOBAL SMALL MOLECULE API REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS, BY APPLICATION (2020) 109
TABLE 3 GLOBAL SMALL MOLECULE VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2019-2027) (MILLION LITRES) 110
TABLE 4 GLOBAL SMALL MOLECULE API PRODUCTION, BY APPLICATION, (2019-2027) (TONS) 111
TABLE 5 GLOBAL BIOLOGICS VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2019-2027) (MILLION LITRES) 114
TABLE 6 GLOBAL SMALL MOLECULE API PRODUCTION, (2019-2027) (METRIC TONS) 115
TABLE 7 GLOBAL BIOLOGICS API PRODUCTION, (2019-2027) (METRIC TONS) 115
TABLE 8 GLOBAL API PRODUCTION, (2019-2027) (METRIC TONS) 116
TABLE 9 PATENT EXPIRY OF SYNTHETIC API DRUGS, (2017 – 2022) 120
TABLE 10 PATENT EXPIRY OF BIOTECH API DRUGS, (2018 – 2028) 124
TABLE 11 ANDA APPROVALS: SMALL MOLECULES - GENERICS, (2020 – 2021) 126
TABLE 12 ANDA APPROVALS: BIOSIMILARS, (2020) 131
TABLE 13 COMPANIES ACQUISITION AND MERGER, (2018 – 2020) 143
TABLE 14 EXPANSIONS, (2019 – 2021) 148
TABLE 15 COLLABORATIONS AND AGREEMENTS, (2019 – 2021) 156
TABLE 16 API GLOBAL MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN) 202
TABLE 17 SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 206
TABLE 18 SYNTHETIC API GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 208
TABLE 19 BRANDED SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 210
TABLE 20 GENERIC SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 212
TABLE 21 BIOTECH API GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN) 215
TABLE 22 BIOTECH API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 217
TABLE 23 MONOCLONAL ANTIBODIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 222
TABLE 24 RECOMBINANT PROTEINS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 225
TABLE 25 VACCINES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 229
TABLE 26 OTHER BIOTECH API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 235
TABLE 27 BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 237
TABLE 28 BIOLOGIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 240
TABLE 29 BIOSIMILAR API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 243
TABLE 30 HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 246
TABLE 31 HPAPI GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 248
TABLE 32 BRANDED HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 250
TABLE 33 GENERIC HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 252
TABLE 34 API GLOBAL MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN) 255
TABLE 35 CAPTIVE API GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN) 258
TABLE 36 CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 259
TABLE 37 BRANDED CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 262
TABLE 38 GENERIC CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 264
TABLE 39 MERCHANT API GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN) 266
TABLE 40 MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 267
TABLE 41 BRANDED MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 269
TABLE 42 GENERIC MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 271
TABLE 43 API GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 273
TABLE 44 SYNTHETIC API GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 275
TABLE 45 BIOTECH API GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 277
TABLE 46 HPAPI GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 279
TABLE 47 INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 288
TABLE 48 SYNTHETIC INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 289
TABLE 49 BIOTECH INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 290
TABLE 50 HPAPI INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 292
TABLE 51 ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 299
TABLE 52 SYNTHETIC ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 300
TABLE 53 BIOTECH ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 301
TABLE 54 HPAPI ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 302
TABLE 55 CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 306
TABLE 56 SYNTHETIC CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 307
TABLE 57 BIOTECH CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 308
TABLE 58 HPAPI CARDIOVASCULAR DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 309
TABLE 59 CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 313
TABLE 60 SYNTHETIC CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 314
TABLE 61 BIOTECH CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 315
TABLE 62 HPAPI CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 316
TABLE 63 PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 319
TABLE 64 SYNTHETIC PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 320
TABLE 65 BIOTECH PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 321
TABLE 66 HPAPI PULMONARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 322
TABLE 67 GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 325
TABLE 68 SYNTHETIC GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 326
TABLE 69 BIOTECH GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 327
TABLE 70 GASTROINTESTINAL DISORDERS HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 328
TABLE 71 ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 331
TABLE 72 SYNTHETIC ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 332
TABLE 73 BIOTECH ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 333
TABLE 74 HPAPI ENDOCRINE DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 334
TABLE 75 METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 338
TABLE 76 SYNTHETIC METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 340
TABLE 77 BIOTECH METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 341
TABLE 78 HPAPI METABOLIC DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 342
TABLE 79 GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 344
TABLE 80 SYNTHETIC GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 345
TABLE 81 BIOTECH GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 346
TABLE 82 HPAPI GENITOURINARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 347
TABLE 83 MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 350
TABLE 84 SYNTHETIC MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 351
TABLE 85 BIOTECH MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 352
TABLE 86 HPAPI MUSCULOSKELETAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 353
TABLE 87 OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 357
TABLE 88 SYNTHETIC OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 358
TABLE 89 BIOTECH OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 359
TABLE 90 HPAPI OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 360
TABLE 91 API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 363
TABLE 92 NORTH AMERICA API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN) 370
TABLE 93 NORTH AMERICA BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN) 371
TABLE 94 NORTH AMERICA SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 372
TABLE 95 NORTH AMERICA BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 373
TABLE 96 NORTH AMERICA HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 374
TABLE 97 NORTH AMERICA API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN) 375
TABLE 98 NORTH AMERICA CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN) 376
TABLE 99 NORTH AMERICA MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN) 377
TABLE 100 NORTH AMERICA API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 378
TABLE 101 NORTH AMERICA SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 379
TABLE 102 NORTH AMERICA BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 380
TABLE 103 NORTH AMERICA HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 381
TABLE 104 NORTH AMERICA API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN) 389
TABLE 105 EUROPE API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN) 415
TABLE 106 EUROPE BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN) 416
TABLE 107 EUROPE SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 417
TABLE 108 EUROPE BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 418
TABLE 109 EUROPE HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 419
TABLE 110 EUROPE API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN) 420
TABLE 111 EUROPE CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN) 421
TABLE 112 EUROPE MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN) 422
TABLE 113 EUROPE API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 423
TABLE 114 EUROPE SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 424
TABLE 115 EUROPE BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 425
TABLE 116 EUROPE HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 426
TABLE 117 EUROPE API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN) 434
TABLE 118 APAC API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN) 473
TABLE 119 APAC BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN) 474
TABLE 120 APAC SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 475
TABLE 121 APAC BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 476
TABLE 122 APAC HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 477
TABLE 123 APAC API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN) 478
TABLE 124 APAC CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN) 479
TABLE 125 APAC MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN) 480
TABLE 126 APAC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 481
TABLE 127 APAC SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 482
TABLE 128 APAC BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 483
TABLE 129 APAC HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 484
TABLE 130 APAC API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN) 492
TABLE 131 ROW API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN) 535
TABLE 132 ROW BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN) 536
TABLE 133 ROW SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 537
TABLE 134 ROW BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 538
TABLE 135 ROW HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN) 539
TABLE 136 ROW API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN) 540
TABLE 137 ROW CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN) 541
TABLE 138 ROW MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN) 542
TABLE 139 ROW API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 543
TABLE 140 ROW SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 544
TABLE 141 ROW BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 545
TABLE 142 ROW HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 546
TABLE 143 ROW API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN) 554
TABLE 144 PRODUCT APPROVALS 579
TABLE 145 AGREEMENTS 590
TABLE 146 EXPANSIONS 598
TABLE 147 COLLABORATIONS 603
TABLE 148 PRODUCT LAUNCH 607
TABLE 149 PARTNERSHIP 610
TABLE 150 ACQUISITIONS 612
TABLE 151 OTHERS 615
TABLE 152 BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN) 625
TABLE 153 BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN) 626
TABLE 154 BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN) 627
TABLE 155 DIVIS LABORATORIES LTD: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN) 635
TABLE 156 DIVIS LABORATORIES LTD: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN) 636
TABLE 157 LONZA GROUP: TOTAL REVENUE & R&D EXPENSES (2018 -2020) ($MN) 641
TABLE 158 LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN) 642
TABLE 159 LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN) 643
TABLE 160 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2019) ($MN) 662
TABLE 161 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN) 663
TABLE 162 PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN) 664
TABLE 163 SANOFI: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN) 675
TABLE 164 SANOFI: TOTAL REVENUE BY SEGMENT (2018-2020) ($MN) 676
TABLE 165 SANOFI: TOTAL REVENUE BY REGION (2018-2020) ($MN) 677
TABLE 166 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN) 687
TABLE 167 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE BY SEGMENT (2018-2020) ($MN) 688
TABLE 168 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE BY GEOGRAPHY (2018-2020) ($MN) 689
TABLE 169 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN) 696
TABLE 170 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN) 697
TABLE 171 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN) 698

Report Title: Active Pharmaceutical Ingredients (API) Global Market - Forecast To 2027


Your Details
Valid Invalid number
LIST OF COMPANIES MENTIONED IN THE REPORT
AARTI DRUGS LTD.
ABBVIE INC.
ABCELLERA BIOLOGICS INC.
ABCLONAL INC.
ACADIA PHARMACEUTICALS INC.
ACETO
ACIC PHARMACEUTICALS INC.
ADIMMUNE CORPORATION
ADVANCE PHARMACEUTICALS, LLC
AILERON THERAPEUTICS INC.
AJANTA PHARMA LIMITED
AJINOMOTO BIO-PHARMA
ALBEMARLE CORPORATION
ALCAMI CORPORATION, INC.
ALEMBIC PHARMACEUTICALS LTD.
ALKEM LABORATORIES LTD.
ALKERMES PLC
ALMAC GROUP
ALMELO PRIVATE LIMITED
ALPIC REMEDIES LTD.
ALVEN LABORATORIES
AMBIO PHARMA INC.
AMEGA BIOTECH S.A.
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC
AMOYTOP BIOTECH
ANGELINI HOLDING S.P.A.
APROGEN
APUTIT LLC
ARAVIVE INC.
ARENA PHARMACEUTICALS, INC.
AREVIPHARMA GMBH
ARTESAN PHARMA GMBH & CO. KG
ASPIRE LIFESCIENCES PVT., LTD.
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
AURINIA PHARMACEUTICALS INC.
AUROBINDO PHARMA LTD.
AVROBIO INC.
AZAD PHARMACEUTICAL INGREDIENTS AG
BACHEM HOLDING AG
BAL PHARMA LTD.
BASF SE
BAXTER INTERNATIONAL INC.
BAYER AG
BIO ELPIDA
BIO GENOMICS LTD.
BIO MARIN PHARMACEUTICALS INC.
BIOCIN HEALTHCARE
BIOCON LTD.
BIOGEN INC.
BIONOW
BIONTECH SE
BIOPHORE INDIA PHARMACEUTICALS PVT LTD
BIOSINT S.P.A.
BIOTECHNICA PHARMA GLOBAL
BIOVIAN
BLANVER FARMOQUIMICA
BOEHRINGER INGELHEIM GMBH
BRAMMER BIO
BRAWN BIOTECH LTD.
BRIGHT PATH LABORATORIES
BRISTOL-MEYERS SQUIBB
CADILA PHARMACEUTICALS LTD.
CARLYLE GROUP (AMRI)
CATALENT INC.
CAYMAN CHEMICAL
CELGENE CORPORATION
CELLTRION HEALTHCARE
CENTURY PHARMACEUTICALS LTD.
CERBIOS - PHARMA S.A.
CFM GROUP (AMSA S.P.A)
CHANGZHOU PHARMACEUTICAL FACTORY
CHEMCON GMBH
CHINA CHEMICAL & PHARMACEUTICAL CO., LTD.
CHONGQING HUAPONT PHARMACEUTICAL CO., LTD.
CIPLA LIMITED
CKD BIO
COBA PHARMA S.L.U
CONSORT MEDICAL PLC.
CORDEN PHARMA INTERNATIONAL GMBH
COSMO PHARMACEUTICALS
CTX LIFE SCIENCES PVT. LTD.
DAIICHI SANKYO COMPANY, LIMITED
DAITO PHARMACEUTICAL CO., LTD.
DALTON PHARMA SERVICES
DCS PHARMA AG
DELPHARM SAS
DISHMAN CARBOGEN AMCIS LIMITED
DIVIS LABORATORIES LTD.
DR. REDDY'S LABORATORIES LTD.
EISAI CO., LTD.
ELI LILLY AND COMPANY
ELUSYS THERAPEUTIC, INC.
EMCURE PHARMACEUTICALS LTD.
ENALTEC LABS PRIVATE LIMITED.
EPRIUS BIOPHARMACEUTICALS INC.
ERCROS S.A
ESTECHPHARMA CO., LTD.
ESTEVE QUÍMICA
EVEREST ORGANICS LIMITED
EVONIK INDUSTRIES AG (EVONIC HEALTHCARE)
F. HOFFMANN-LA ROCHE LTD
FABBRICA ITALIANA SINTETICI S.P.A.
FAREVA S.A
FARMABIOS SPA
FARMHISPANIA GROUP
FERRER GROUP (INTERQUIM, S.A.)
FERRING PHARMACEUTICALS
FLAMMA S.P.A.
FLORENTIS PHARMACEUTICALS PVT., LTD.
FORMOSA LABORATORIES INC.
FRESENIUS SE & CO. KGAA
FUJIFILM CORPORATION
GENEREX BIOTECHNOLOGY CORPERATION
GENTEC PHARMACEUTICAL GROUP S.A
GILEAD SCIENCES, INC.
GLAXOSMITHKLINE PLC
GLENMARK GENERICS LTD.
GNOSIS S.P.A.
GRANULES INDIA LTD.
GVK INDUSTRIES LIMITED (GVK BIOSCIENCE)
HAOYUAN CHEMEXPRESS CO.LTD.
HARBOUR BIOMED
HARMAN FINOCHEM LIMITED
HENI CHEMICAL INDUSTRIES
HERAUES HOLDING GMBH
HETERO LABS LTD.
HONOUR LAB LTD.
HOVIONE
HUVAPHARMA
HYBIO PHARMACEUTICAL CO., LTD.
IBIO INC
ICROM SPA
INABATA FRANCE S.A.S.
INALCO S.P.A.
INDENA S.P.A
INPELLIS INC.
INTAS PHARMACEUTICALS LTD.
JEIL PHARMACEUTICAL CO. LTD.
JOHNSON & JOHNSON
JUBILANT LIFE SCIENCES
KATSURA CHEMICAL CO.,LTD.
KBI BIOPHARMA, INC.
KERN PHARMA, S.L.
KLEOS PHARMA
KONGO YAKUHIN CO., LTD.
KOSHER PHARMACEUTICALS
KYORIN HOLDINGS, INC. (KYORIN PHARMACEUTICAL CO., LTD.)
LANNETT CO. INC.
LAURUS LABS.
LEBSA
LGM PHARMA
LIBBS FARMACÊUTICA
LIPTIS PHARMACEUTICALS USA INC.
LONZA GROUP
LOTUS PHARMACEUTICAL CO., LTD.
LUPIN LIMITED
LUSOCHIMICA S.P.A
MACLEODS PHARMACEUTICAL LTD.
MAGLE CHEMOSWED AB
MALLINCKRODT PHARMACEUTICALS
MEDICHEM S.A
MEGAFINE PHARMA LTD
MEHTA API
MERCK KGAA
METROCHEM API
MICRO LABS LTD.
MINAKEM S.A
MOEHS IBERICA S.L.
MOLCAN CORPORATION
MOREPEN LABORATORIES LTD.
MSN LABORATORIES PVT.LTD.
MVIYES PHARMA VENTURES PRIVATE LIMITED
NATCO PHARMA LTD.
NEOVACS
NEULAND LABORATORIES LTD
NEURAXPHARM ARZNEIMITTEL GMBH
NIFTY LABS PVT LTD.
NORCHIM SAS
NOVARTIS INTERNATIONAL AG
NOVASEP HODLINGS SAS
NOVO NORDISK A/S
NOVOCAP S.A.
NUCLIUS LIFESCIENCES
OFICHEM B.V.
OLAINFARM AS
OLON S.P.A
OPTIMUS PHARMA PRIVATE LTD.
OPTUM, INC.
ORGENESIS INC.
ORION OY (FERMION OY)
OUTLOOK THERAPEUTICS, INC.
PARATEK PHARMACEUTICALS INC.
PERMIRA FUNDS (CAMBREX CORPORATION)
PERRIGO COMPANY PLC
PERSONALIZED STEM CELLS, INC.
PFANSTIEHL INC.
PFIZER INC.
PHARMACEUTICAL INTERNATIONAL INC.
PHARMAZELL GROUP
PHYTON BIOTECH LLC
PIERRE FABRE GROUP
PIRAMAL PHARMA SOLUTIONS
POLPHARMA B2B
PRAJNA GENERICS PVT. LTD.
PRECISE GROUP
PRECISION BIOSCIENCES, INC.
PRINCETON BIOMOLECULAR RESEARCH INC
PROBIOGEN AG
PROZOMIX LIMITED
RAKS PHARMA PVT LTD.
RECIPHARM AB
REGENERON PHARMACEUTICALS, INC.
REINE LIFESCIENCE
REVA PHARMA PVT., LTD.
RINQUE PHARMA S.A
ROCHEM INTERNATIONAL INC.
RPG LIFE SCIENCES LTD.
RXN CHEMICALS PVT. LTD.
SAAMYA BIOTECH (INDIA) LTD.
SAJJALA BIO LABS
SAMSUNG BIOLOGICS CO. LTD.
SANECA PHARMACEUTICALS A.S.
SANOFI S.A.
SCINOPHARM TAIWAN LTD.
SEATTLE GENETICS INC.
SEQENS GROUP
SERENITY PHARMACEUTICALS CORP
SERMONIX PHARMACEUTICALS
SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., LTD.
SHANGHAI HENLIUS BIOTECH, INC.
SHENZHEN HAORUI INDUSTRIAL DEV.
SHILPA MEDICARE LIMITED
SHIONO CHEMICAL CO., LTD.
SHIONOGI & CO. LTD.
SHREEJI PHARMA INTERNATIONAL
SICHUAN CLOVER BIOPHARMACEUTICALS, INC.
SIEGFRIED HOLDINNGS AG
SM BIOMED SDN. BHD
SMILAX LABORATORIES LIMITED
SMS PHARMACEUTICALS LIMITED
SPARK THERAPEUTICS
SRINI PHARMACEUTICALS LTD.
STADA ARZNEIMITTEL AG
STANDARD CHEMICAL & PHARMACEUTICAL CO.
STERLING BIOTECH LTD.
SUMITOMO DAINIPPON PHARMA CO., LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD.
SUVEN LIFE SCIENCE LTD
SUZHOU RYWAY BIOTECH
SYMBIOTEC PHARMA LAB PVT., LTD
SYNERGENE ACTIVE INGREDIENTS PVT, LTD.
SYN-TECH CHEM. AND PHARMA.CO., LTD.
TAKEDA PHARMACEUTICAL COMPANY LTD.
TARO PHARMACEUTICAL INDUSTRIES LTD.
TB ALLIANCE
TEMAD CO.
TETRAPHASE PHARMACEUTICAL INC.
TEVA PHARMACEUTICAL INDUSTRIES LTD
THERAPEUTICMD INC.
THERAVANCE BIOPHARMA, INC.
THERMO FISHER SCIENTIFIC
TIGENIX NV
TONIX PHARMACEUTICALS
TORRENT PHARMACEUTICALS, LTD.
TPG BIOTECH
TRENZYME GMBH
TRIMAX BIO SCIENCES (P) LIMITED
UMICORE N.V.
UNICHEM LABORATORIES LTD.
UNION QUIMICO FARMACEUTICA, S.A.
UNIQUE BIOTECH LTD.
USV PRIVATE LTD.
VAISHALI PHARMA LTD.
VERTEX PHARMACEUTICALS
VIATRIS INC. (MYLAN N.V./UPJOHN PFIZER INC.)
VIR BIOTECHNOLOGY, INC.
VIRUJ PHARMACEUTICALS PVT, LTD.
VIVIMED LABS LTD.
WANBURY LTD.
WAVELENGTH PHARMACEUTICALS
WELT CARE LIFESCIENCES PVT., LTD.
WOCKHARDT
WUXI APPTEC (STA PHARMACEUTICAL CO., LTD.)
WUXI BIOLOGICS
XELLIA PHARMACEUTICALS
XIAMEN AMOYTOP BIOTECH CO., LTD.
YABAO PHARMACEUTICAL GROUP CO., LTD.
YUNG ZIP CHEMICAL INDUSTRIAL CO., LTD.
ZAMBON GROUP (ZACH)
ZCL CHEMICALS LTD.
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
ZYDUS CADILA

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Genome-Based Drug Companies in China

Genome-Based Drug Companies in China

Biologics Companies in China

Biologics Companies in China

Bladder Cancer Treatment Drugs Companies in China

Bladder Cancer Treatment Drugs Companies in China

Health Care  Companies in China

Health Care Companies in China

Cardiovascular Drugs Companies in China

Cardiovascular Drugs Companies in China

Cancer Treatment Drugs Companies in China

Cancer Treatment Drugs Companies in China